[go: up one dir, main page]

TN2013000440A1 - Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids - Google Patents

Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids

Info

Publication number
TN2013000440A1
TN2013000440A1 TNP2013000440A TN2013000440A TN2013000440A1 TN 2013000440 A1 TN2013000440 A1 TN 2013000440A1 TN P2013000440 A TNP2013000440 A TN P2013000440A TN 2013000440 A TN2013000440 A TN 2013000440A TN 2013000440 A1 TN2013000440 A1 TN 2013000440A1
Authority
TN
Tunisia
Prior art keywords
methyl
organic acids
imidazol
pyridinyl
pyrimidinyl
Prior art date
Application number
TNP2013000440A
Other languages
English (en)
Inventor
Shoufeng Li
Saran Kumar
Nikhil Javant Kavimandan
Enxian Lu
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2012/042205 external-priority patent/WO2012174082A1/fr
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TN2013000440A1 publication Critical patent/TN2013000440A1/fr

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TNP2013000440A 2011-09-30 2013-10-29 Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids TN2013000440A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161541306P 2011-09-30 2011-09-30
PCT/US2012/042205 WO2012174082A1 (fr) 2011-06-14 2012-06-13 Libération modifiée de 4-méthyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-méthyl-1h-imidazol-1-yl)-3-(trifluorométhyl)phényl] benzamide solubilisé à l'aide d'acides organiques

Publications (1)

Publication Number Publication Date
TN2013000440A1 true TN2013000440A1 (en) 2015-03-30

Family

ID=52394773

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2013000440A TN2013000440A1 (en) 2011-09-30 2013-10-29 Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids

Country Status (2)

Country Link
CU (1) CU20130165A7 (fr)
TN (1) TN2013000440A1 (fr)

Also Published As

Publication number Publication date
CU20130165A7 (es) 2014-04-24

Similar Documents

Publication Publication Date Title
SG194756A1 (en) Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids
PH12016501310B1 (en) Pharmaceutical compositions comprising azd9291
EA201291421A1 (ru) Пероральные фармацевтические лекарственные формы, содержащие дабигатрана этексилат и его фармацевтически приемлемые соли
SG10201810985XA (en) Tofacitinib oral sustained release dosage forms
EA201491285A1 (ru) Улучшенные композиции и способы доставки омепразола и ацетилсалициловой кислоты
IL233282A (en) Crystalline Forms of 5- (2,6-Di-4-Morpholinyl-4-Pyrimidinyl) -4-Trifluoromethylpyridine-2-Amine Monohydrochloride
EA201201263A1 (ru) Фармацевтическая композиция, содержащая этексилат дабигатрана
TN2012000371A1 (en) Pyrazole compounds as crth2 antagonists
EA201201202A1 (ru) Пероральная фармацевтическая композиция, содержащая этексилат дабигатрана
PH12015500823A1 (en) Modified release formulations for oprozomib
IL230487B (en) 6-(n-(7-chloro-1-hydroxy-3,1-dihydrobenzo[c][1,2]oxaborole-5-yl)methylsulfonamido)-5-cyclopropyl-2-(4-fluorophenyl)-n- Methylbenzofuran-3-carboxamide, their salts and pharmaceutical preparations containing them
JO3587B1 (ar) أشكال جرعات بينداموستين عن طريق الفم
TN2014000177A1 (en) Immediate release 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-methyl- 1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide formulation
IN2014CN02343A (en) Oral formulations containing hyaluronic acid for sustained drug release
TR201803451T4 (tr) Olmesartan formülasyonlari.
TN2013000440A1 (en) Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids
IN2012CH05549A (fr)
WO2011161223A3 (fr) Formes pharmaceutiques à usage oral comprenant de la lercanidipine et de l'énalapril et leurs sels pharmaceutiquement acceptables
TH148311A (th) การปลดปล่อยที่ถูกดัดแปรของ 4-เมธิล-3-[[4-(3-ไพริดินิล)-2-ไพริมิดินิล]อะมิโน]-n-[5-(4-เมธิล-1h-อิมิดาโซล-1-อิล)-3-(ไตรฟูลออโรเมธิล)ฟีนิล] เบนซาไมด์ที่สามารถละลายได้โดยใช้กรดอินทรีย์
MA35169B1 (fr) Libération modifiée de 4-méthyl-3-[ [4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4- méthyl-1h-imidazol-1-yl)-3-(trifluorométhyl)phényl] benzamide solubilisé à l'aide d'acides organiques
TH148311B (th) การปลดปล่อยที่ถูกดัดแปรของ 4-เมธิล-3-[[4-(3-ไพริดินิล)-2-ไพริมิดินิล]อะมิโน]-n-[5-(4-เมธิล-1h-อิมิดาโซล-1-อิล)-3-(ไตรฟูลออโรเมธิล)ฟีนิล] เบนซาไมด์ที่สามารถละลายได้โดยใช้กรดอินทรีย์
MY183976A (en) Pharmaceutical composition for oral administration with improved dissolution and/or absorption
TR201005911A2 (tr) Geliştirilmiş dissolüsyon profiline sahip bir ilaç formülasyonu.
UA110792C2 (uk) Лікарська форма бендамустину для перорального застосування
ES2422657A1 (es) Composición farmacéutica sólida de cilostazol